Henry Meds Prescribing Data and Outcomes Signals: An Independent Review

What Is Henry Meds and How Does Its Model Work?

Henry Meds operates as a subscription-based telehealth service focused on metabolic and hormonal health, with compounded GLP-1 receptor agonists as its flagship offering. Patients pay a monthly or quarterly cash fee, complete an online intake form, and receive asynchronous or synchronous provider consultations before a prescription is sent to a partner compounding pharmacy.

The Cash-Pay Compounding Model

The cash-pay model bypasses insurance entirely. That lowers the sticker price compared to branded semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro), which carry list prices exceeding $900 per month without coverage. Compounded versions have been marketed at $150 to $350 per month by various platforms, including Henry Meds.

The tradeoff is regulatory. Compounded drugs are exempt from the FDA's premarket approval process under 21 U.S.C. § 503A and § 503B, meaning they do not go through the same efficacy and safety review as brand-name products. The FDA has stated explicitly that compounded drugs are not FDA-approved, carry no guarantee of sterility or potency equivalence, and may differ in inactive ingredients that affect absorption. [1]

Provider Oversight and Prescription Practices

Asynchronous telehealth, where a patient fills out a questionnaire and a provider reviews it without a live visit, is legal in most states but raises questions about the depth of clinical evaluation. The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines require a documented BMI of 30 kg/m² or higher, or BMI of 27 kg/m² with at least one weight-related comorbidity, before initiating pharmacotherapy. [2] Whether every Henry Meds intake adequately captures comorbidity data is not publicly verifiable.

Does Henry Meds Have Published Outcomes Data?

No peer-reviewed study has reported weight-loss or metabolic outcomes specific to Henry Meds patients. This is the most important gap in evaluating the platform against competitors or branded agents.

What the Branded-Agent Trials Show

The absence of platform-specific data means any outcomes estimate must rely on trials of the active pharmaceutical ingredient, not the compounded formulation. For semaglutide 2.4 mg subcutaneous, the STEP-1 trial (N=1,961) showed a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). [3] STEP-4 (N=803) showed that discontinuing semaglutide after 20 weeks of run-in led to weight regain of approximately 6.9 percentage points by week 68, underscoring the chronic-disease nature of obesity pharmacotherapy. [4]

For tirzepatide, the SURMOUNT-1 trial (N=2,539) demonstrated mean weight loss of 20.9% at 72 weeks with the 15 mg dose versus 3.1% placebo (P<0.001). [5] These outcomes are for FDA-approved formulations manufactured under current Good Manufacturing Practice (cGMP) controls.

Why Compounded Formulations May Not Replicate Trial Results

Compounded semaglutide is typically manufactured as the base or as a salt (semaglutide sodium or semaglutide acetate) rather than the free-base form used in Ozempic and Wegovy. The FDA noted in its March 2024 guidance that these alternative salt forms have not been shown to be bioequivalent to the approved products. [6] Potency can also vary: a 2024 analytical testing report circulated by Eli Lilly found that some compounded tirzepatide vials contained between 80% and 115% of the labeled dose, a variance range wider than the 90% to 110% specification required for approved drugs. [7]

The table below outlines how compounded GLP-1 products differ from FDA-approved agents across five clinical-decision dimensions.

| Dimension | FDA-Approved Agent | Compounded Agent | |---|---|---| | Efficacy evidence | Phase 3 RCT data (STEP, SURMOUNT) | Assumed from active ingredient; no RCT | | Manufacturing standard | cGMP, FDA-inspected facility | 503A/503B pharmacy, less frequent inspection | | Bioequivalence | Established | Not established for salt variants | | Post-market safety reporting | MedWatch required | Voluntary | | Shortage-list eligibility | N/A | Only legal during active FDA shortage |

FDA Regulatory Actions Affecting Henry Meds and Similar Platforms

Semaglutide Shortage Resolution

The FDA removed semaglutide from the drug shortage list in March 2024, triggering a wind-down period for 503A compounding pharmacies. The agency set a final deadline of April 22, 2025 for 503A pharmacies to stop compounding semaglutide. [8] Platforms that continued dispensing compounded semaglutide after that date operated outside the legal compounding framework unless they fell under a narrow individualized patient exception.

Tirzepatide Shortage Resolution

Tirzepatide was removed from the shortage list in October 2024. The FDA subsequently issued guidance in March 2025 setting a similar phase-out timeline for 503A pharmacies, with a compliance date of May 22, 2025. [9] Platforms still offering compounded tirzepatide to new patients after that date face enforcement risk, and patients face supply interruption.

FDA Warning Letters to Compounding Pharmacies

The FDA issued multiple warning letters to 503B outsourcing facilities in 2023 and 2024 related to GLP-1 compounding. One letter to a major outsourcing facility cited failures in sterility assurance, inadequate beyond-use dating procedures, and lack of proper identity testing for semaglutide starting material. [10] Henry Meds has not itself received a publicly available FDA warning letter as of July 2025, but its partner pharmacies are subject to these same standards, and the platform does not publicly disclose which 503A or 503B facilities it uses.

LegitScript Certification

LegitScript, the verification service used by Google, Meta, and other ad platforms to approve healthcare advertisers, requires telehealth pharmacies and prescribers to meet specific standards for state licensure, prescribing practices, and drug legality. As of mid-2025, Henry Meds does not appear on LegitScript's list of certified telehealth providers, a status that limits its ability to advertise on major ad networks and signals unmet compliance benchmarks. [11]

Henry Meds Complaints: What Public Records Show

BBB Complaint Patterns

The Better Business Bureau profile for Henry Meds (operating as Henry Inc.) shows the company is not BBB-accredited as of mid-2025. Consumer complaints filed with the BBB cluster around three themes: difficulty canceling subscriptions, unexpected charges after enrollment, and delays in receiving medications. [12] Billing disputes are the most frequently cited category, consistent with patterns seen at other subscription telehealth companies.

BBB complaints are not clinical-outcomes data. They reflect customer-service friction more than medical harm. Still, subscription cancellation difficulty is a specific concern for GLP-1 platforms because patients who cannot easily discontinue service may continue paying for medications they cannot use after shortage-related supply interruptions.

State Medical Board and Pharmacy Board Actions

No state medical board disciplinary action naming Henry Meds or its affiliated providers has appeared in publicly searchable databases (Federation of State Medical Boards, individual state board sites) as of this review. This is a notable absence of negative signal, not a positive endorsement. The asynchronous prescribing model used by Henry Meds is newer than most board enforcement cycles, and complaint-to-action timelines typically run 12 to 36 months. [13]

MedWatch Adverse Event Reports

The FDA's MedWatch Adverse Event Reporting System (FAERS) database contains reports of adverse events associated with compounded semaglutide and tirzepatide products, including nausea, vomiting, hypoglycemia, and injection-site reactions. [14] FAERS data does not identify the dispensing platform in most cases, so Henry Meds-specific adverse event counts cannot be extracted. The FDA has noted that compounded GLP-1 reports to FAERS increased substantially in 2023 and 2024, coinciding with the surge in platform-based compounding prescriptions. [15]

How Henry Meds Compares to FDA-Approved Alternatives

Cost vs. Clinical Evidence Tradeoff

The price difference between compounded and branded GLP-1 agents is real. Wegovy (semaglutide 2.4 mg) has a list price of approximately $1,349 per month as of 2025, though manufacturer savings programs can reduce out-of-pocket cost to $0 for commercially insured patients and $25 per month for eligible uninsured patients through Novo Nordisk's savings card. [16] For patients genuinely unable to access manufacturer assistance, compounded agents at $200 to $300 per month represent a meaningful access improvement.

The clinical evidence tradeoff is equally real. Every milligram of weight-loss data cited in FDA label language, every cardiovascular outcome signal from SELECT (N=17,604, 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg), and every safety signal tracked through post-market surveillance applies to the approved formulation, not to a compounded variant. [17]

Prescribing Quality Signals

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy specifies that prescribers should document baseline weight, BMI, blood pressure, fasting glucose or HbA1c, and relevant comorbidities before initiating GLP-1 therapy. [18] Telehealth platforms that rely solely on self-reported height and weight in an online form cannot verify these parameters. A 2022 JAMA Internal Medicine study of direct-to-consumer telehealth prescribing found that 43% of online weight-loss prescription encounters lacked documentation of contraindications screening. [19]

What a High-Quality GLP-1 Prescriber Should Do

The American Gastroenterological Association's 2022 clinical practice update on obesity pharmacotherapy states: "Pharmacotherapy for obesity should be used as an adjunct to lifestyle intervention and should be continued indefinitely if effective and tolerated, as weight regain occurs after discontinuation." [20] A platform that does not provide structured dietary and behavioral support alongside prescribing is delivering an incomplete standard of care, regardless of whether it uses compounded or branded agents.

Is Henry Meds Legit? A Clinical and Regulatory Assessment

"Legit" means different things in different contexts. Henry Meds is a registered U.S. Company with licensed prescribers in its network. Prescriptions issued through its platform are legal in states where its providers hold licensure. Those facts make it a functioning business, not a scam in the criminal sense.

Where Legitimacy Gets Complicated

Legitimacy as a clinical-quality question is harder. The compounded products it has dispensed since its shortage-period authorization are not FDA-approved. The bioequivalence of its semaglutide salt formulations to Ozempic or Wegovy has not been established. The prescribing process does not demonstrably meet AACE or Endocrine Society documentation standards for all patients. And the platform's legal basis for continuing to prescribe compounded semaglutide after April 22, 2025 relies on narrow individualized compounding exceptions that may not apply to the volume prescribing typical of telehealth platforms.

The FDA's Own Language

The FDA's April 2025 guidance on compounded semaglutide stated: "Patients who are currently receiving compounded semaglutide should talk to their healthcare provider about transitioning to an FDA-approved product." [21] That is a direct federal recommendation to transition away from the compounded products that are the core of Henry Meds' business model.

Red Flags to Watch

Patients considering Henry Meds should ask four specific questions before enrolling:

1. Which compounding pharmacy fills the prescription, and does it hold 503B outsourcing facility registration?
2. Does the prescriber review a complete medical intake including documented comorbidities, not just self-reported BMI?
3. What is the platform's plan for continuity of supply given the FDA shortage-list removals?
4. What is the cancellation policy, and are recurring charges clearly disclosed before enrollment?

None of these questions has a publicly documented answer specific to Henry Meds as of this review.

Clinical Bottom Line

Patients seeking GLP-1 pharmacotherapy deserve the weight-loss and cardiovascular outcome data that backed the FDA-approval decisions for semaglutide and tirzepatide. Henry Meds offers lower-cost access, but that access comes through compounded products that do not carry the same evidence base, are no longer legally compoundable at scale under 503A rules after April-May 2025 shortage-list removals, and have generated a pattern of billing-related consumer complaints. Any prescriber initiating GLP-1 therapy should document baseline HbA1c, blood pressure, and comorbidities per Endocrine Society 2023 guideline standards before the first injection. [18]